Gene Expression in MS Patients Before and During Treatment With Interferon-beta

S. Andrea Hospital

Status: Terminated

Conditions: Multiple Sclerosis

Study type: Observational

Funder types: Other

Identifiers

NCT00202384

NEU - FCG - 02

Details and patient eligibility

About

Clinical and experimental evidences suggest that there is a variability in therapeutic response to immunomodulating therapies in Multiple Sclerosis patients.

Microarrays is a technology that permits to monitor the expression levels of thousands of genes at a time.

The specific aim of this study is to identify predictive factors of therapeutic response in MS patients treated with high-dose Interferon-Beta.

Enrollment: 600 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosis of relapsing-remitting MS (McDonald criteria)
• age between 18-55
• EDSS less or equal to 5.5

Exclusion criteria

• use of any other disease modifying drugs
• use of corticosteroids during 3 months before starting protocol
• clinical relapse during 1 month before starting protocol
• serious heart, renal, hepatic or haematological dysfunction defined by laboratory exams